Press releases

202420232022202120202019201820172016201520142013
Press release 2024/09/18
Medivir to present at the Pareto Securities Healthcare Conference

Stockholm, Sweden, September 16, 2024 — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer...

Read more
Press release 2024/09/16
Medivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO

Mature results from Medivir’s phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced...

Read more
Press release 2024/09/12
Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/08/22 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2024

“Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer”     April –...

Read more
Press release 2024/07/18
Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/06/28 Regulatory
Number of shares and votes in Medivir AB on 28 June 2024

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during...

Read more
Press release 2024/06/27
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI

New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular...

Read more
Press release 2024/06/19
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/05/30
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 7 May 2024...

Read more
Press release 2024/05/30
Medivir to present at Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/05/23
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/05/07 Regulatory
Resolutions at the Annual General Meeting in Medivir on 7 May 2024

Medivir Aktiebolag (publ) held its annual general meeting today on 7 May 2024. The annual general meeting was held by physical...

Read more